KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to -$2.2 billion.

  • Regeneron Pharmaceuticals' Cash from Financing Activities fell 13.23% to -$717.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 billion, marking a year-over-year decrease of 169.39%. This contributed to the annual value of -$2.2 billion for FY2024, which is 22.93% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cash from Financing Activities of -$2.2 billion as of FY2024, which was down 22.93% from -$1.8 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities peaked at -$1.0 billion during FY2021, and registered a low of -$2.2 billion during FY2024.
  • Its 3-year average for Cash from Financing Activities is -$1.7 billion, with a median of -$1.8 billion in 2023.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Cash from Financing Activities plummeted by 681.63% in 2020, and later spiked by 48.96% in 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities (Yearly) stood at -$2.0 billion in 2020, then soared by 48.96% to -$1.0 billion in 2021, then decreased by 0.32% to -$1.0 billion in 2022, then slumped by 77.41% to -$1.8 billion in 2023, then decreased by 22.93% to -$2.2 billion in 2024.